Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

Core Insights - Myriad Genetics, Inc. has partnered with INTERLINK Care Management to improve education and access to hereditary cancer testing for CancerCARE for Life members [1][4] - The agreement allows over one million individuals in CancerCARE's network to evaluate their eligibility for the MyRisk test through the MyGeneHistory quiz [2][3] Company Overview - Myriad Genetics is a leader in genetic and genomic tumor testing and precision medicine, focusing on advancing health and well-being through genetic insights [6] - The company offers the MyRisk with RiskScore Hereditary Cancer Test, which evaluates 48 genes linked to hereditary cancer risk and provides personalized risk assessments for various cancers [3][4] Industry Context - CancerCARE for Life is one of the largest cancer prevention and management programs in the U.S., combining education with personalized care to enhance member experiences [5] - The collaboration aims to increase access to genetic screening, enabling patients to make informed decisions regarding their health [4][5]